Home Clinical Trial Updates

Clinical Trial Updates

Clinical trial updates

Phase 2b Study Investigates NFX-179 for the Treatment of Cutaneous Neurofibromas

Danielle Garcia - January 10, 2023

Capivasertib plus Fulvestrant Shows Statistically Significant and Clinical Improvement in PFS

Attendees during morning sessions of the 2018 San Antonio Breast cancer Symposium. Courtesy 2018 AACR

Updated Interim Analysis of Phase 3 monarchE Trial: Abemaciclib Shows Absolute Improvement in IDFS

ASH 2022: Positive OS Data for Patients in R/R AML in Phase 1 Actimab-A + CLAG-M Combination Trial

Active Surveillance May be an Effective Option for Low-risk Thyroid Cancer

US FDA Grants Priority Review for the CD20xCD3 T-cell Engaging Bispecific...

Editorial Team - July 6, 2022

$High-Dose Ifosfamide is Superior for Treating Recurrent and Primary Refractory Ewing Sarcoma$

High-Dose Ifosfamide is Superior for Treating Recurrent and Primary Refractory Ewing...

Peter Hofland, Ph.D - June 5, 2022

ASCO 2022: Servier Commits to Bringing the Promise of Tomorrow to...

Editorial Team - June 1, 2022

Colorectal cancer

Pivotal Phase 2 Clinical Trial Shows Positive Results with Tucatinib +...

Editorial Team - May 23, 2022

Study: Isatuximab Combination Provides Unprecedented Median PFS in Treatment of Multiple...

Peter Hofland, Ph.D - May 15, 2022

ALL Patients With Certain Gene Regulation Patterns May Be Less Likely...

Editorial Team - April 12, 2022

First Pateint Dosed with Allogeneic, off-the-shelf, Invariant Natural Killer T-cell Therapy

Editorial Team - March 3, 2022

Merck | MSD Exhibition booth at the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Pembrolizumab Shows Significantly Prolonged Event-free Survival in High-Risk Early-Stage TNBC

Editorial Team - February 9, 2022

Why Taking a Less Personalized Approach May Increase Access to Cancer...

Laurent Levy - February 2, 2022

Zanidatamab Shows Encouraging Antitumor Activity in Heavily Pretreated HER2-Positive Breast Cancer

Editorial Team - December 9, 2021

12 3...26 Page 1 of 26

LATEST NEWS

Study: Blocking Immune Suppressor Cells in Mice with Glioblastoma Improves Survival

Danielle Garcia - January 27, 2023

Stephen Spellman: Mismatched Unrelated Donors – Key to Erasing the Gap in Donor Availability...

Editorial Team - January 18, 2023

New Technologies in Post-surgical Wound Dressings

Brad Greer, JD - January 16, 2023

The Patient Journey Tech Stack: 10 Predictions for 2023

Yishai Knobel - January 16, 2023

Study Confirms: ‘Extreme Lack of Consistency’ Hampers the Potential of Nanosized Medicines

Danielle Garcia - January 12, 2023

Press Releases | Cancer

Java Original Coffee Company to Support The Onco’Zine Brief Radio... January 25, 2023
The Java Original Coffee Company, the home of incredible artisan roasted gourmet coffee, is committed to support the cancer research community as well as select individuals and organizations involved...(PRWeb January 25, 2023)Read the full story at https://www.prweb.com/releases/java_original_coffee_company_to_support_the_oncozine_brief_radio_broadcast_and_podcast/prweb19133000.htm
GO2 for Lung Cancer Addresses Disparities and Health Inequities... January 23, 2023
Through efforts in awareness, education and readily available resources, GO2 for Lung Cancer is helping underserved communities access information and education needed to increase survival rates.(PRWeb January 23, 2023)Read the full story at https://www.prweb.com/releases/go2_for_lung_cancer_addresses_disparities_and_health_inequities_head_on_in_underserved_communities/prweb19126525.htm
$1.3 Billion Liquid Biopsy Market the Present and Future of Clinical... January 20, 2023
Dramatic changes have occurred in the global liquid biopsy market that continue to impact how medical professionals diagnosis, treat, and monitor cancer.(PRWeb January 20, 2023)Read the full story at https://www.prweb.com/releases/1_3_billion_liquid_biopsy_market_the_present_and_future_of_clinical_oncology/prweb19123773.htm